News Archive

Science2Startup (S2S) is back! In April 2020, we were planning the 3rd annual S2S conference for university-focused biotech entrepreneurship – but it was unfortunately scuttled by COVID. A subsequent event in 2021 was also precluded by the pandemic. But as we all regain some normalcy, so too with S2S. We’re relaunching the event on May 3, 2023 at the Broad Institute.

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones.

Nimbus Therapeutics will receive $4 billion upfront in one of the largest biotech licensing deals in recent years.

We just held our 2022 Annual General Meeting for our investors, and a few weeks ago convened our Atlas Venture Retreat – both in person for the first time in 3 years. Kicking off each of these meetings is our “Year In Review” presentation, which covers a broad range of macro themes, the biotech ecosystem, and our firm.

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its thirteenth fund, raising $450 million in an oversubscribed fundraise.